Newsroom | 5014 results
Sorted by: Latest
-
INTENT Biologics Receives FDA Agreement Granting a Full Waiver for its Pediatric Study Plan for PEP Biologic™ in Advanced Wound Care
ROCHESTER, Minn.--(BUSINESS WIRE)--INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has agreed to INTENT’s Initial Pediatric Study Plan (iPSP) for PEP Biologic™ under IND 019567, supporting the company’s request for a full pediatric waiver for its forthcoming Biologics License Applicati...
-
Soley Therapeutics Announces Breakthrough Research Demonstrating How Cellular Stress Responses Reveal Drug Mechanisms, Enabling Entirely New and Accelerated Methods for Drug Discovery
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Soley Announces Breakthrough Research Demonstrating How Cellular Stress Responses Reveal Drug Mechanisms, Enabling New Methods for Drug Discovery...
-
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Fourth Quarter 2025 Earnings Call.” The conference call will be webcast live and a lin...
-
Vida Health Partners with RxSaveCard to Reduce Rising GLP-1 Costs
SAN FRANCISCO--(BUSINESS WIRE)--Vida Health today announced the launch of Vida Self-Pay (Powered by RxSaveCard) to help employers reduce prescription drug costs....
-
Smart Meter Launches iGlucose® Touch, a Touchscreen, Cellular-Connected Blood Glucose Meter Built for Modern RPM
TAMPA, Fla.--(BUSINESS WIRE)--As demand accelerates for simpler, more reliable remote patient monitoring solutions, Smart Meter, the leading supplier of cellular-enabled Remote Patient Monitoring (RPM) devices, data, and services, today announced the launch of iGlucose® Touch, a next-generation blood glucose monitoring system engineered to modernize glucose testing while delivering dependable, real-time data to care teams. Purpose-built for RPM, iGlucose Touch addresses long-standing challenges...
-
People Magazine Spotlights Tiffany Howard’s Metabolic Health Journey with OPTAVIA®
BALTIMORE--(BUSINESS WIRE)--Medifast® (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system OPTAVIA, celebrates the inspiring health transformation of Tiffany Howard, recently featured in People magazine. Tiffany’s journey highlights how OPTAVIA’s comprehensive program, which combines science-backed nutrition, personalized coaching and sustainable habit-building, reversed her metabolic dysfunction1. For Tiffany, this meant several meaningful he...
-
Riassunto: InterAx e Alveus annunciano un accordo strategico di licenza e di ricerca per sviluppare un candidato terapeutico differenziato per una malattia metabolica
ZURIGO, PHILADELPHIA e COPENHAGEN, Danimarca--(BUSINESS WIRE)--InterAx Biotech Ltd (“InterAx”) e Alveus Therapeutics Inc. (“Alveus”) oggi hanno annunciato un accordo strategico di licenza e collaborazione alla ricerca volto a sviluppare un candidato differenziato a piccola molecola per la malattia metabolica per offrire una terapia dimagrante durevole con tollerabilità superiore. Questa collaborazione fa parte di uno impegno di ricerca congiunta su un target e una modalità di interesse terapeut...
-
Samenvatting: InterAx en Alveus kondigen strategische onderzoeks- en licentieovereenkomst aan voor ontwikkeling van onderscheidend therapeutisch kandidaatmedicijn voor stofwisselingsziekten
ZÜRICH & PHILADELPHIA & KOPENHAGEN, Denemarken--(BUSINESS WIRE)--InterAx Biotech Ltd ('InterAx') en Alveus Therapeutics Inc. ('Alveus') hebben vandaag een strategische samenwerkings- en licentieovereenkomst aangekondigd voor de ontwikkeling van een onderscheidend kandidaatmedicijn met kleine moleculen voor stofwisselingsziekten, gericht op duurzaam gewichtsverlies met een superieure verdraagbaarheid. Dit partnerschap vormt een gezamenlijke onderzoeksinspanning gericht op een doelwit en modalite...
-
InterAx und Alveus kündigen strategische Forschungs- und Lizenzvereinbarung zur Entwicklung eines differenzierten therapeutischen Arzneimittelkandidaten für Stoffwechselerkrankungen an
ZÜRICH, PHILADELPHIA UND KOPENHAGEN, Dänemark--(BUSINESS WIRE)--InterAx Biotech Ltd („InterAx“) und Alveus Therapeutics Inc. („Alveus“) haben heute eine strategische Forschungskooperation und Lizenzvereinbarung zur Entwicklung eines differenzierten niedermolekularen Arzneimittelkandidaten für Stoffwechselerkrankungen bekannt gegeben, der eine dauerhafte Gewichtsreduktion bei hervorragender Verträglichkeit verspricht. Im Rahmen dieser Partnerschaft wird eine gemeinsame Forschungsinitiative zu ei...
-
InterAx et Alveus annoncent un accord stratégique de recherche et contrat de licence pour développer un candidat thérapeutique différencié pour les maladies métaboliques
ZURICH, PHILADELPHIE et COPENHAGUE, Danemark--(BUSINESS WIRE)--InterAx Biotech Ltd (« InterAx ») et Alveus Therapeutics Inc. (« Alveus ») ont annoncé aujourd'hui un accord de collaboration stratégique en matière de recherche et contrat de licence visant à développer une petite molécule candidate différenciée pour les maladies métaboliques afin d'obtenir une perte de poids durable ayant une meilleure une tolérance. Ce partenariat s'inscrit dans une recherche conjointe sur une cible et une modali...
